What Is Endometriosis

Endometriosis is a chronic inflammatory condition in which tissue that resembles the endometrium (the lining of the uterus) grows in locations outside the uterine cavity, most commonly on the ovaries, fallopian tubes, and pelvic peritoneum. These ectopic lesions respond to hormonal cycles, leading to local bleeding, scarring, adhesions, and persistent inflammation. The condition affects a substantial fraction of people with uteruses during their reproductive years and is a leading cause of pelvic pain and infertility.

Endometriosis is not simply a painful period condition. It is a systemic inflammatory disease with measurable effects on immune function, hormonal balance, energy metabolism, and long-term tissue integrity. Chronic inflammation from endometriotic lesions drives oxidative stress, elevates pro-inflammatory cytokines, and can alter the function of distant organs over time. These same inflammatory processes are central to accelerated biological aging, meaning that unmanaged endometriosis creates a persistent internal environment associated with earlier onset of age-related decline.

From a longevity perspective, the condition also intersects with fertility, metabolic health, and mental wellbeing. Chronic pain alters the stress response, disrupts sleep architecture, and can contribute to sustained cortisol elevation. The hormonal disruptions associated with endometriosis, particularly estrogen dominance and progesterone resistance, ripple outward to affect bone density, cardiovascular risk, and cognitive function over decades. Addressing endometriosis is therefore not only about managing symptoms in the short term but about reducing cumulative inflammatory and hormonal burden across the lifespan.

The most commonly discussed origin theory is retrograde menstruation, where menstrual blood carrying endometrial cells travels backward through the fallopian tubes and deposits in the pelvic cavity. Because retrograde menstruation occurs in most menstruating people but only a fraction develop endometriosis, something else must be at play. Current understanding points to a combination of immune surveillance failure (the body does not clear the displaced cells), genetic susceptibility (multiple gene loci are associated with risk), and an altered peritoneal environment that permits implantation and growth.

Once established, endometriotic lesions behave as semi-autonomous tissue. They express aromatase, an enzyme that converts androgens to estrogen locally, creating a self-sustaining estrogen supply that promotes lesion growth independent of ovarian estrogen production. They also demonstrate progesterone resistance, meaning they fail to respond to progesterone's normal anti-proliferative signals. This hormonal imbalance drives continued proliferation and inflammation within and around the lesions. The lesions recruit immune cells, particularly macrophages and natural killer cells with altered function, which paradoxically promote angiogenesis (new blood vessel formation) and tissue remodeling rather than clearing the ectopic tissue.

The resulting chronic inflammation produces adhesions, fibrous bands of scar tissue that can bind organs together and distort pelvic anatomy. In deep infiltrating endometriosis, lesions penetrate more than five millimeters into affected tissue and can involve the bowel, bladder, ureters, and diaphragm. The nervous system becomes implicated as well: endometriotic lesions can develop their own nerve supply through a process called neuroangiogenesis, and central sensitization can amplify pain signals over time, so that the pain experience persists even after lesion removal.

Estrogen is the primary hormonal driver of endometriosis. Ectopic lesions express aromatase, an enzyme absent in normal endometrium, which allows them to synthesize estrogen locally from circulating androgens. This creates a positive feedback loop: locally produced estrogen stimulates prostaglandin E2 production, which in turn upregulates further aromatase activity. The result is a self-sustaining estrogenic microenvironment that persists even when ovarian estrogen output is suppressed.

Progesterone resistance is the other side of the hormonal equation. Healthy endometrium responds to progesterone by halting proliferation and promoting decidualization. In endometriotic tissue, progesterone receptor expression (particularly the PR-B isoform) is markedly reduced, meaning the tissue fails to respond to progesterone's restraining signals. This dual problem of estrogen excess and progesterone resistance explains why the condition persists across the menstrual cycle and why simply supplementing progesterone is not always sufficient.

The broader hormonal landscape also matters. Elevated cortisol from chronic pain and stress can suppress progesterone production via the pregnenolone steal pathway. Impaired hepatic estrogen clearance and gut dysbiosis (which affects the estrobolome, the collection of gut microbes that metabolize estrogen) can elevate circulating estrogen levels. Addressing endometriosis hormonally therefore requires attention to the full metabolic chain of hormone production, receptor sensitivity, and elimination.

The hallmark symptom is pelvic pain that typically worsens around menstruation, though many individuals experience pain throughout the cycle. Dysmenorrhea (painful periods), dyspareunia (pain during intercourse), and dyschezia (painful bowel movements) are common presentations. Pain does not always correlate with disease stage; some people with extensive lesions report mild discomfort while others with minimal visible disease experience severe, debilitating pain, likely due to differences in nerve involvement and central sensitization.

Beyond pain, endometriosis produces a constellation of systemic signals. Fatigue that is disproportionate to activity levels is reported frequently and likely reflects the metabolic cost of chronic inflammation. Bloating and gastrointestinal symptoms (sometimes called "endo belly") can mimic irritable bowel syndrome, leading to misdiagnosis. Cyclical shoulder or chest pain may indicate diaphragmatic endometriosis. Heavy or irregular menstrual bleeding, urinary urgency, and lower back pain round out the symptom profile. Subfertility, discovered when attempting conception, is sometimes the first clinical clue.

Treatment falls broadly into hormonal, surgical, and supportive categories, and the optimal combination depends on disease location, severity, symptom burden, and fertility goals. Hormonal therapies aim to suppress estrogen's stimulatory effect. Options include combined oral contraceptives (continuous use to suppress menstruation), progestins (oral, injectable, or intrauterine), and GnRH agonists or the newer GnRH antagonists (such as elagolix and relugolix), which create a low-estrogen state. These approaches manage symptoms but do not eliminate lesions, and symptoms generally return after discontinuation.

Surgical excision, in which lesions are carefully cut out rather than burned (ablated), is considered the gold standard for tissue confirmation and more complete disease removal. Performed laparoscopically by surgeons who specialize in endometriosis, excision surgery aims to restore normal anatomy and reduce pain. For ovarian endometriomas, cystectomy (removing the cyst wall) is generally preferred over drainage alone. In severe cases involving bowel, bladder, or ureteral lesions, multidisciplinary surgical teams may be necessary.

Supportive and integrative strategies serve as adjuncts rather than replacements. Anti-inflammatory dietary patterns, pelvic floor physical therapy for associated muscle dysfunction, acupuncture for pain modulation, and targeted supplementation (omega-3 fatty acids, N-acetylcysteine, curcumin) are used by some practitioners alongside conventional treatment. The evidence base for these approaches ranges from small clinical trials to observational reports, and their role is best understood as part of a broader inflammation-management strategy rather than as standalone treatments.

Large-scale genomic studies have identified multiple susceptibility loci for endometriosis, though no single gene explains the condition. Epidemiological research consistently shows associations between endometriosis and increased risk of ovarian cancer subtypes (clear cell and endometrioid), cardiovascular disease, and autoimmune disorders, though causality remains debated. Surgical excision by experienced specialists is supported by observational evidence showing superior long-term symptom control and lower recurrence compared to ablation, but high-quality randomized trials directly comparing the two are limited. Hormonal therapies, including combined oral contraceptives, progestins, and GnRH agonists or antagonists, are well studied for symptom suppression, though they do not eradicate disease and symptoms typically recur after discontinuation.

Research into anti-inflammatory and dietary approaches is growing but still largely consists of small observational studies and pilot trials. Preliminary work on the gut microbiome's role in estrogen metabolism (the estrobolome concept) has generated interest in microbiome-targeted interventions, but clinical data specific to endometriosis outcomes remain sparse. Biomarker research has not yet produced a reliable non-invasive diagnostic test, though several candidates, including CA-125, microRNAs, and cytokine panels, are under investigation. The gap between symptom onset and diagnosis, often spanning many years, remains one of the most significant clinical challenges.

Endometriosis management often involves trade-offs. Hormonal suppression therapies carry side effects including bone density loss (with GnRH agonists), mood changes, and metabolic shifts. Surgical excision, while often effective, involves operative risks and requires a surgeon with specific expertise in endometriosis to minimize damage to surrounding structures. Repeated surgeries can themselves contribute to adhesion formation. Delaying treatment in the hope that symptoms will self-resolve can allow disease progression and may reduce fertility options over time. Anyone navigating treatment decisions benefits from working with a clinician who specializes in this condition rather than relying on generalist approaches.